Thalidomide suppresses melanoma growth by activating natural killer cells in mice.
Thalidomide suppresses melanoma growth by activating natural killer cells in mice.
复制标题
DOI:
10.3892/or.16.6.1231
复制
发表时间:
2006-12
期刊:
影响因子:
4.2
通讯作者:
Ai Kawamata;D. Ito;Takeshi Odani;T. Isobe;M. Iwase;M. Hatori;M. Nagumo
中科院分区:
文献类型:
--
作者:
Ai Kawamata;D. Ito;Takeshi Odani;T. Isobe;M. Iwase;M. Hatori;M. Nagumo
Although thalidomide (Thd) is being extensively investigated for its effects on cytokine production and T cell costimulation, it is poorly understood whether it is capable of modulating the activities of natural killer (NK) cells. In this study, Thd effects on NK cell activity were examined with a murine model of melanoma, which is mostly rejected by NK cell-dependent mechanism. Administration of Thd significantly (p<0.01 on Day 21) suppressed the growth of subcutaneous B16F1 melanoma. In Thd-treated mice, marked splenomegaly and augmented splenocyte count were observed. Additionally, the percentage of splenic NK1.1+ cells was elevated to approximately 2.5-fold within 10 days after Thd treatment. The expression of interferon inducible protein (IP)-10, interferon (IFN)-gamma, interleukin (IL)-12 and IL-18 was remarkably upregulated. Production of the cytotoxic molecule perforin was also augmented. These data suggest that Thd strongly activates NK cell activity in mice, possibly resulting in enhanced tumor surveillance defense.